Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry

HC Wainwright Trims Cardiff Oncology (NASDAQ:CRDF) Target Price to $14.00

Financial News Live ·  {{timeTz}}

Cardiff Oncology (NASDAQ:CRDF – Get Rating) had its target price reduced by HC Wainwright from $22.00 to $14.00 in a report issued on Friday morning, The Fly reports. They currently have a buy rating on the stock.

Several other analysts also recently weighed in on CRDF. Piper Sandler dropped their target price on shares of Cardiff Oncology from $7.00 to $5.00 and set an overweight rating for the company in a report on Tuesday, September 13th. Robert W. Baird dropped their price target on shares of Cardiff Oncology from $9.00 to $6.00 and set an outperform rating for the company in a research note on Monday, August 29th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of Buy and a consensus price target of $9.75.

Get Cardiff Oncology alerts:

Cardiff Oncology Stock Performance

CRDF stock opened at $1.73 on Friday. The firm has a market cap of $74.92 million, a PE ratio of -1.94 and a beta of 1.38. The firm's 50 day moving average price is $2.51 and its 200-day moving average price is $2.13. Cardiff Oncology has a one year low of $1.13 and a one year high of $7.63.

Cardiff Oncology (NASDAQ:CRDF – Get Rating) last posted its earnings results on Thursday, August 4th. The company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.01. Cardiff Oncology had a negative net margin of 9,841.41% and a negative return on equity of 28.82%. The firm had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.08 million. Equities research analysts predict that Cardiff Oncology will post -1.04 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO James E. Levine bought 30,000 shares of the stock in a transaction that occurred on Friday, September 16th. The stock was purchased at an average price of $1.56 per share, for a total transaction of $46,800.00. Following the completion of the purchase, the chief financial officer now owns 60,000 shares in the company, valued at approximately $93,600. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 3.50% of the company's stock.

Hedge Funds Weigh In On Cardiff Oncology

A number of institutional investors and hedge funds have recently modified their holdings of CRDF. Quantbot Technologies LP purchased a new stake in Cardiff Oncology in the first quarter valued at $28,000. LPL Financial LLC lifted its position in Cardiff Oncology by 17.9% in the second quarter. LPL Financial LLC now owns 26,384 shares of the company's stock valued at $58,000 after acquiring an additional 3,998 shares during the last quarter. XTX Topco Ltd purchased a new stake in Cardiff Oncology in the first quarter valued at $62,000. Price T Rowe Associates Inc. MD lifted its position in Cardiff Oncology by 69.9% in the second quarter. Price T Rowe Associates Inc. MD now owns 36,500 shares of the company's stock valued at $80,000 after acquiring an additional 15,020 shares during the last quarter. Finally, GSA Capital Partners LLP purchased a new stake in Cardiff Oncology in the fourth quarter valued at $93,000. Institutional investors and hedge funds own 20.70% of the company's stock.

Cardiff Oncology Company Profile

(Get Rating)

Cardiff Oncology, Inc, a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.

Featured Articles

  • Get a free copy of the StockNews.com research report on Cardiff Oncology (CRDF)
  • Oracle's Short-Term Pain Could Be Your Long-Term Gain
  • Lucid is Looking Like a Clear EV Winner
  • Still Lovin' It: Investors Keep Visiting McDonald's
  • Did FedEx Just Deliver A Buying Opportunity?
  • Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight

Receive News & Ratings for Cardiff Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiff Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors’ financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.

Moomoo is a financial information and trading app offered by Moomoo Technologies Inc.
In the U.S., investment products and services available through the moomoo app are offered by Moomoo Financial Inc., a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and a member of Financial Industry Regulatory Authority (FINRA)/Securities Investor Protection Corporation (SIPC).
In Singapore, investment products and services available through the moomoo app are offered through Moomoo Financial Singapore Pte. Ltd. regulated by the Monetary Authority of Singapore (MAS). Moomoo Financial Singapore Pte. Ltd. is a Capital Markets Services Licence (License No. CMS101000) holder with the Exempt Financial Adviser Status. This advertisement has not been reviewed by the Monetary Authority of Singapore.
In Australia, financial products and services available through the moomoo app are provided by Futu Securities (Australia) Ltd, an Australian Financial Services Licensee (AFSL No. 224663) regulated by the Australian Securities and Investment Commission (ASIC). Please read and understand our Financial Services Guide, Terms and Conditions, Privacy Policy and other disclosure documents which are available on our websites https://www.futuau.com and https://www.moomoo.com/au. Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd. and Futu Securities (Australia) Ltd are affiliated companies.